Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Sensus price target raised to $17.50 from $17 at Alliance Global Partners » 12:29
08/05/22
08/05
12:29
08/05/22
12:29
SRTS

Sensus Healthcare

$14.07 /

+2.93 (+26.30%)

Alliance Global Partners…

Alliance Global Partners analyst Ben Haynor raised the firm's price target on Sensus Healthcare to $17.50 from $17 and keeps a Buy rating on the shares post the Q2 results. Management expects profitability to continue the remainder of the year and sounded upbeat about their prospects for a strong second half given their "robust" backlog," Haynor tells investors in a research note. The analyst views the Q2 print positively and is "most intrigued by the signal sent by the company launching both television and digital media advertising."

ShowHide Related Items >><<
SRTS Sensus Healthcare
$14.07 /

+2.93 (+26.30%)

SRTS Sensus Healthcare
$14.07 /

+2.93 (+26.30%)

05/06/22 H.C. Wainwright
Sensus Healthcare price target raised to $16 from $13
03/03/22 H.C. Wainwright
Sensus Healthcare price target raised to $13 from $12 at H.C. Wainwright
02/14/22 H.C. Wainwright
Sensus Healthcare price target raised to $12 from $10 at H.C. Wainwright
01/06/22 Maxim
Sensus Healthcare price target raised to $12 from $7 at Maxim
SRTS Sensus Healthcare
$14.07 /

+2.93 (+26.30%)

Earnings
Sensus Healthcare reports Q2 EPS 21c vs (2c) last year » 16:30
08/04/22
08/04
16:30
08/04/22
16:30
SRTS

Sensus Healthcare

$11.12 /

-0.055 (-0.49%)

Reports Q2 revenue…

Reports Q2 revenue $12.1M, consensus $9.55M. "I'm delighted with our continued strong financial performance, with significant year-over-year revenue growth and continued profitability," said Joe Sardano, chairman and chief executive officer of Sensus Healthcare. "We remain focused on our core dermatology business, building upon the initiatives we put in place during the past two years, leveraging improved reimbursement for superficial radiation therapy to treat non-melanoma skin cancers and keloids, offering an attractive fair value lease program to physician customers, maintaining an active presence at dermatology conferences and trade shows and, most recently, implementing a new marketing campaign that includes both digital and television platforms. More than half our customers have purchased premium-featured SRT-100 Vision(TM) systems under a leasing agreement, while approximately 80% of systems coming off a one-year warranty continue with a service agreement, providing a significant source of recurring revenue."

ShowHide Related Items >><<
SRTS Sensus Healthcare
$11.12 /

-0.055 (-0.49%)

SRTS Sensus Healthcare
$11.12 /

-0.055 (-0.49%)

05/06/22 H.C. Wainwright
Sensus Healthcare price target raised to $16 from $13
03/03/22 H.C. Wainwright
Sensus Healthcare price target raised to $13 from $12 at H.C. Wainwright
02/14/22 H.C. Wainwright
Sensus Healthcare price target raised to $12 from $10 at H.C. Wainwright
01/06/22 Maxim
Sensus Healthcare price target raised to $12 from $7 at Maxim
SRTS Sensus Healthcare
$11.12 /

-0.055 (-0.49%)

Hot Stocks
Sensus Healthcare takes order for 10 Transdermal Infusion Systems » 08:15
07/27/22
07/27
08:15
07/27/22
08:15
SRTS

Sensus Healthcare

$9.71 /

-0.95 (-8.91%)

Sensus Healthcare…

Sensus Healthcare announces the sale of 10 Transdermal Infusion Systems to Hair Enhancement Centers, HEC, a rapidly-growing chain of Texas-based hair loss treatment centers. The Systems will be used to non-invasively deliver U.SK Under Skin's hair-health serum Skin Savers Hair. U.SK Under Skin is a subsidiary of privately-held EMS Pharma, the largest pharmaceutical company in Brazil and itself a subsidiary of Grupo NC, one of Brazil's largest conglomerates.Sensus will deliver two Systems during the third quarter of 2022 and the remaining Systems during the fourth quarter. "I am impressed with HEC's progress, expanding from two clinics to nine already so far year to date, with expectations for more clinics over the coming months," said Joe Sardano, chairman and chief executive officer of Sensus Healthcare. "We are delighted to support their future clinic growth with our TransDermal Infusion System to deliver U.SK Under Skin's hair-health serum. Hair growth renewal is an important indication as it impacts about 50 million American men and 30 million American women with male- or female-pattern baldness, according to the Cleveland Clinic."

ShowHide Related Items >><<
SRTS Sensus Healthcare
$9.71 /

-0.95 (-8.91%)

SRTS Sensus Healthcare
$9.71 /

-0.95 (-8.91%)

05/06/22 H.C. Wainwright
Sensus Healthcare price target raised to $16 from $13
03/03/22 H.C. Wainwright
Sensus Healthcare price target raised to $13 from $12 at H.C. Wainwright
02/14/22 H.C. Wainwright
Sensus Healthcare price target raised to $12 from $10 at H.C. Wainwright
01/06/22 Maxim
Sensus Healthcare price target raised to $12 from $7 at Maxim
SRTS Sensus Healthcare
$9.71 /

-0.95 (-8.91%)

Hot Stocks
Sensus Healthcare announces expansion of relationship with CSU » 08:07
07/20/22
07/20
08:07
07/20/22
08:07
SRTS

Sensus Healthcare

$10.19 /

+0.325 (+3.30%)

Sensus Healthcare…

Sensus Healthcare announces the expansion of its relationship with Colorado State University, CSU, College of Veterinary Medicine and Biomedical Studies with the acquisition of a second SRT-100 system by CSU. Studies at CSU's new Johnson Family Equine Hospital in Fort Collins are expected to be conducted primarily in ophthalmic indications. "We are excited to continue our relationship with Sensus Healthcare and look forward to expanding our work to include horses," said Kathryn Wotman, Assistant Professor at CSU. Commenting on the agreement, John Heinrich, Ph.D., member of the Sensus Healthcare board of directors and the key relationship contact with CSU, added, "We are delighted to expand our relationship with the Colorado State School of Veterinary Medicine with a second SRT system. The recent dedication of the Johnson Family Equine Hospital provides an ideal environment for the cooperative implementation and validation of equine oncological applications of our technology."

ShowHide Related Items >><<
SRTS Sensus Healthcare
$10.19 /

+0.325 (+3.30%)

SRTS Sensus Healthcare
$10.19 /

+0.325 (+3.30%)

05/06/22 H.C. Wainwright
Sensus Healthcare price target raised to $16 from $13
03/03/22 H.C. Wainwright
Sensus Healthcare price target raised to $13 from $12 at H.C. Wainwright
02/14/22 H.C. Wainwright
Sensus Healthcare price target raised to $12 from $10 at H.C. Wainwright
01/06/22 Maxim
Sensus Healthcare price target raised to $12 from $7 at Maxim
SRTS Sensus Healthcare
$10.19 /

+0.325 (+3.30%)

Over a quarter ago
Recommendations
Sensus Healthcare price target raised to $16 from $13 » 11:21
05/06/22
05/06
11:21
05/06/22
11:21
SRTS

Sensus Healthcare

$7.81 /

+0.68 (+9.54%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Yi Chen raised the firm's price target on Sensus Healthcare to $16 from $13 and reiterates a Buy rating on the shares. The company's Q1 beat demonstrated strong momentum as patient visits to dermatologists' office have returned to and above the pre-pandemic levels, Chen tells investors in a research note. The analyst now believes Sensus' top- and bottom-line growth in 2022 could be higher than prior expectations.

ShowHide Related Items >><<
SRTS Sensus Healthcare
$7.81 /

+0.68 (+9.54%)

SRTS Sensus Healthcare
$7.81 /

+0.68 (+9.54%)

03/03/22 H.C. Wainwright
Sensus Healthcare price target raised to $13 from $12 at H.C. Wainwright
02/14/22 H.C. Wainwright
Sensus Healthcare price target raised to $12 from $10 at H.C. Wainwright
01/06/22 Maxim
Sensus Healthcare price target raised to $12 from $7 at Maxim
12/02/21 H.C. Wainwright
Sensus Healthcare price target raised to $10 from $9 at H.C. Wainwright
SRTS Sensus Healthcare
$7.81 /

+0.68 (+9.54%)

Earnings
Sensus Healthcare reports Q1 EPS 97c, consensus 33c » 17:01
05/05/22
05/05
17:01
05/05/22
17:01
SRTS

Sensus Healthcare

$7.13 /

-0.39 (-5.19%)

Reports Q1 revenue $103M,…

Reports Q1 revenue $103M, consensus $6.73M. "Revenues for the first quarter reflect a sharpened focus on our core dermatology business, and we are pleased with the revenue growth we continue to achieve," said Joe Sardano, chairman and chief executive officer of Sensus Healthcare. "During the quarter we sold our non-core asset for $15.0 million in cash and recorded a gain on asset sale of $12.8 million. This cash will primarily be used to fund future growth of our dermatology products and services. We launched TransDermal Infusion into the U.S. market which has tremendous potential in eliminating the need for needle injections allowing for more procedure to be less painful for patients. Also, our board of directors has approved a $3.0 million share repurchase program that we intend to deploy thoughtfully and in the best interest of our stockholders." Mr. Sardano continued, "We established a fair market value leasing program in January 2021, which continues to be well received and supported the sales growth of SRT-100 Vision systems. This product, with its premium functionality and image-guided ultrasound, now accounts for the vast majority of domestic SRT system sales. The upward revaluation of reimbursement codes by the Centers for Medicare and Medicaid Services has made the return on investment for our systems even more compelling. In addition, with increased sales of Vision systems we are selling significantly more service contracts. Approximately one-half of our customers are now under Extended Warranty Service Agreements, compared with just 25% a few years ago, providing Sensus with a growing base of recurring revenues."The resumption of in-person trade shows has been deeply gratifying. These events allow us to reconnect with customers, showcase our products and build high-caliber sales leads. We were delighted to highlight our TransDermal Infusion System for non-invasive drug delivery for skin rejuvenation treatments, pre-laser treatments and pre- and post-plastic surgery at the Winter Clinical in Hawaii, and at the American Academy of Dermatology conference in Boston. We are excited about the potential for this system, in particular for the delivery of finasteride, commonly known as Propecia, for hair growth. Dr. Glynis Ablon, a key opinion leading dermatologist with the Ablon Skin Institute and Research Center, and Associate Clinical Professor at UCLA is studying the delivery of finasteride with our TransDermal System. We believe her work will validate the system's excellent utility for this indication." Mr. Sardano concluded, "During the first quarter we hired nine sales representatives, returning our sales organization to pre-pandemic levels. We continue to be confident in our sales and earnings trajectory as supported by a robust organization, excellent products backed by rigorous research, creative methods of financing and a committed management team. Despite current geopolitical events, we continue to be highly optimistic about our prospects."

ShowHide Related Items >><<
SRTS Sensus Healthcare
$7.13 /

-0.39 (-5.19%)

SRTS Sensus Healthcare
$7.13 /

-0.39 (-5.19%)

03/03/22 H.C. Wainwright
Sensus Healthcare price target raised to $13 from $12 at H.C. Wainwright
02/14/22 H.C. Wainwright
Sensus Healthcare price target raised to $12 from $10 at H.C. Wainwright
01/06/22 Maxim
Sensus Healthcare price target raised to $12 from $7 at Maxim
12/02/21 H.C. Wainwright
Sensus Healthcare price target raised to $10 from $9 at H.C. Wainwright
SRTS Sensus Healthcare
$7.13 /

-0.39 (-5.19%)

Hot Stocks
Sensus Healthcare announces mata mata turtle treated with SRT-100 system » 08:19
03/24/22
03/24
08:19
03/24/22
08:19
SRTS

Sensus Healthcare

$11.01 /

-0.05 (-0.45%)

Sensus Healthcare…

Sensus Healthcare announces that a mata mata turtle has joined the growing list of animal species successfully treated with Sensus Healthcare's SRT-100 system. Tiffany Martin, DVM, MS, Assistant Professor, Radiation Oncology at Colorado State University Veterinary Teaching Hospital applied superficial radiation therapy, SRT, to the turtle's squamous cell carcinoma in June 2021. The female turtle, which resides at Denver Zoo, showed no signs of the lesion three months after therapy, and continues to be cancer-free as of today. Dr. Martin has used SRT to treat a variety of tumor types including three squamous cell carcinomas, three mast cell tumors, two plasma cell tumors and two soft tissue sarcomas in 12 animals, including five dogs, five cats, a horse and the turtle.

ShowHide Related Items >><<
SRTS Sensus Healthcare
$11.01 /

-0.05 (-0.45%)

SRTS Sensus Healthcare
$11.01 /

-0.05 (-0.45%)

03/03/22 H.C. Wainwright
Sensus Healthcare price target raised to $13 from $12 at H.C. Wainwright
02/14/22 H.C. Wainwright
Sensus Healthcare price target raised to $12 from $10 at H.C. Wainwright
01/06/22 Maxim
Sensus Healthcare price target raised to $12 from $7 at Maxim
12/02/21 H.C. Wainwright
Sensus Healthcare price target raised to $10 from $9 at H.C. Wainwright
SRTS Sensus Healthcare
$11.01 /

-0.05 (-0.45%)

Hot Stocks
Sensus Healthcare announces $3M share repurchase program » 08:12
03/09/22
03/09
08:12
03/09/22
08:12
SRTS

Sensus Healthcare

$9.63 /

+0.43 (+4.67%)

Sensus Healthcare…

Sensus Healthcare announces that its Board of Directors has authorized a program to purchase up to $3,000,000 of shares of its Common Stock. Commenting on this new program, Joe Sardano, chairman and chief executive officer of Sensus Healthcare, said, "With optimism about the future of Sensus, along with the business tracking toward sustained profitability, it just makes sense to invest in ourselves. Acquiring our own shares is one of the ways we plan to use our resources to continue to build shareholder value. Our financial performance, disciplined and thoughtful approach to capital allocation and expenses, and overall strength of our balance sheet give us both the confidence and the flexibility to execute this share repurchase program."

ShowHide Related Items >><<
SRTS Sensus Healthcare
$9.63 /

+0.43 (+4.67%)

SRTS Sensus Healthcare
$9.63 /

+0.43 (+4.67%)

03/03/22 H.C. Wainwright
Sensus Healthcare price target raised to $13 from $12 at H.C. Wainwright
02/14/22 H.C. Wainwright
Sensus Healthcare price target raised to $12 from $10 at H.C. Wainwright
01/06/22 Maxim
Sensus Healthcare price target raised to $12 from $7 at Maxim
12/02/21 H.C. Wainwright
Sensus Healthcare price target raised to $10 from $9 at H.C. Wainwright
SRTS Sensus Healthcare
$9.63 /

+0.43 (+4.67%)

Recommendations
Sensus Healthcare price target raised to $13 from $12 at H.C. Wainwright » 06:14
03/03/22
03/03
06:14
03/03/22
06:14
SRTS

Sensus Healthcare

$10.79 /

+0.39 (+3.75%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Yi Chen raised the firm's price target on Sensus Healthcare to $13 from $12 and keeps a Buy rating on the shares. The Sculptura divestment provides non-dilutive capital to drive the company's commercial expansion in dermatology, Chen tells investors in a research note.

ShowHide Related Items >><<
SRTS Sensus Healthcare
$10.79 /

+0.39 (+3.75%)

SRTS Sensus Healthcare
$10.79 /

+0.39 (+3.75%)

02/14/22 H.C. Wainwright
Sensus Healthcare price target raised to $12 from $10 at H.C. Wainwright
01/06/22 Maxim
Sensus Healthcare price target raised to $12 from $7 at Maxim
12/02/21 H.C. Wainwright
Sensus Healthcare price target raised to $10 from $9 at H.C. Wainwright
11/09/21 Roth Capital
Roth Capital remains bullish on Sensus, ups target to $6.25 after Q3 results
SRTS Sensus Healthcare
$10.79 /

+0.39 (+3.75%)

Hot Stocks
Sensus Healthcare sells Sculptura assets to Empyrean Medical Systems for $15M » 08:08
03/02/22
03/02
08:08
03/02/22
08:08
SRTS

Sensus Healthcare

$10.37 /

-0.13 (-1.24%)

Sensus Healthcare…

Sensus Healthcare announces it has sold its Sculptura assets to Empyrean Medical Systems for $15M in cash. The sale, completed on February 25, 2022, included inventory of Sculptura systems and parts, in addition to all related intellectual property. "Sculptura will be in excellent, capable hands under the ownership of Empyrean, and we wish them all the best in their endeavors with this fabulous technology," said Joe Sardano, chairman and chief executive officer of Sensus Healthcare. "Given the rebound in sales of Sensus' SRT systems and in the dermatology market as a whole, we believe our resources are best focused on our core dermatology business. Sensus has already begun to expand its dermatology product offerings with the recent additions of the TransDermal(TM) Infusion non-invasive drug delivery system as well as Sensus Laser Systems, and we intend to use the proceeds from this sale to expand even further."

ShowHide Related Items >><<
SRTS Sensus Healthcare
$10.37 /

-0.13 (-1.24%)

SRTS Sensus Healthcare
$10.37 /

-0.13 (-1.24%)

02/14/22 H.C. Wainwright
Sensus Healthcare price target raised to $12 from $10 at H.C. Wainwright
01/06/22 Maxim
Sensus Healthcare price target raised to $12 from $7 at Maxim
12/02/21 H.C. Wainwright
Sensus Healthcare price target raised to $10 from $9 at H.C. Wainwright
11/09/21 Roth Capital
Roth Capital remains bullish on Sensus, ups target to $6.25 after Q3 results
SRTS Sensus Healthcare
$10.37 /

-0.13 (-1.24%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.